Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical announced that its independently developed Class I innovative drug TQA3605, a core protein allosteric modulator for chronic hepatitis B, has successfully completed a Phase II clinical trial in combination with nucleos(t)ide analogues, meeting its primary endpoint. In a 122-patient, randomized, double-blind, placebo-controlled, multi-centre study, adding once-daily TQA3605 to standard nucleos(t)ide analogue therapy for 24 weeks significantly increased the proportion of patients achieving HBV DNA levels below the limit of quantification to around 90% across all dose groups, far exceeding the control arm, while maintaining a favourable safety profile with no new safety signals. Against the backdrop of tens of millions of chronic HBV patients in China, low diagnosis and treatment rates, and the limitations of existing long-term nucleos(t)ide analogue therapy, the positive data reinforce TQA3605’s potential as a first-in-class CpAM globally, with convenient once-daily oral administration and no cross-resistance with current treatments, potentially strengthening Sino Biopharmaceutical’s position in liver disease therapeutics and offering a promising new option for HBV patients who are non- or partial responders to current drugs.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a Hong Kong–listed pharmaceutical group that develops and commercialises innovative drugs, with a focus on therapies for major diseases prevalent in China. Its portfolio includes treatments targeting liver diseases such as chronic hepatitis B, where it aims to address significant unmet medical needs in a large patient population with low diagnosis and treatment rates.
Average Trading Volume: 68,803,894
Technical Sentiment Signal: Buy
Current Market Cap: HK$116.6B
See more data about 1177 stock on TipRanks’ Stock Analysis page.